Key facts
- Thyroid signal: Rodent C-cell tumour findings led to a precautionary thyroid cancer warning; not confirmed in humans
- Pancreatic cancer: Early concerns not supported by large clinical trials or meta-analyses
- Colorectal cancer: Some observational data suggest a possible reduced risk in GLP-1 RA users, likely related to weight loss
- Breast cancer: No increased risk identified in clinical trials; weight loss may lower post-menopausal risk
- Regulatory position: Neither MHRA, EMA nor FDA has issued a cancer safety alert for GLP-1 RAs beyond the thyroid precaution
- Obesity-cancer link: Obesity is an established risk factor for at least 13 cancer types; effective weight management may reduce this risk
Why the question matters
With millions of people worldwide now taking GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy), liraglutide (Saxenda) and tirzepatide (Mounjaro), questions about long-term safety — particularly cancer risk — are entirely reasonable. These medications are often taken for years or indefinitely, and patients deserve a clear, evidence-based understanding of what is known.
This guide examines the evidence for each major cancer type that has been discussed in relation to GLP-1 RAs, drawing on clinical trial data, observational studies and the positions of UK and European regulators.
Thyroid cancer: the established safety signal
The most well-known cancer-related concern with GLP-1 RAs is the rodent thyroid C-cell tumour finding. We cover this in detail in our dedicated GLP-1 and thyroid risk guide. In summary:
- Rodent studies showed that GLP-1 RAs caused medullary thyroid carcinoma (MTC) in rats and mice at supratherapeutic doses
- Human thyroid C-cells express far fewer GLP-1 receptors than rodent C-cells
- Large clinical trials have not confirmed an increased MTC risk in humans
- The contraindication for patients with MTC or MEN2 remains in place as a precaution
Pancreatic cancer
Concerns about GLP-1 RAs and pancreatic cancer emerged in the early 2010s, driven by case reports and pharmacovigilance database analyses. The biological rationale was that GLP-1 RAs stimulate pancreatic beta-cell proliferation, and there were questions about whether this trophic effect might extend to ductal cells or exacerbate pre-existing pancreatic lesions.
What the evidence shows
- Clinical trials: The major cardiovascular outcome trials (SUSTAIN-6, LEADER, REWIND, SURPASS) did not identify an increased incidence of pancreatic cancer in GLP-1 RA groups compared with placebo. These trials involved tens of thousands of patients followed for two to five years.
- Meta-analyses: A 2021 Cochrane-style meta-analysis pooling data from multiple GLP-1 RA trials found no statistically significant increase in pancreatic malignancy.
- Regulatory reviews: Both the EMA and US FDA conducted independent reviews of the pancreatic safety data in 2013–2014 and concluded that there was insufficient evidence to establish a causal association between incretin-based therapies and pancreatic cancer.
Pancreatitis distinction: GLP-1 RAs can cause acute pancreatitis in rare cases (estimated at fewer than 1 in 1,000 patients). Chronic pancreatitis is a known risk factor for pancreatic cancer. This indirect pathway may have contributed to early safety signals, but does not establish that GLP-1 RAs directly cause pancreatic cancer.
Colorectal cancer
Colorectal cancer is the fourth most common cancer in the UK, and obesity is a well-established risk factor. Given that GLP-1 RAs produce significant weight loss, researchers have investigated whether they might reduce colorectal cancer risk.
Observational evidence
Several large observational studies using healthcare databases have examined the association:
- A 2024 population-level study using US claims data found that GLP-1 RA users with type 2 diabetes had a significantly lower incidence of colorectal cancer compared with users of other diabetes medications (insulin, sulfonylureas), even after adjusting for BMI and other confounders.
- Scandinavian registry studies have reported similar trends, with GLP-1 RA exposure associated with a 15 to 25 per cent lower relative risk of colorectal cancer compared with non-GLP-1 diabetes treatments.
These findings are consistent with the known link between weight loss and reduced colorectal cancer risk, but observational studies cannot prove causation. Confounding by indication (GLP-1 RA users may be different from non-users in unmeasured ways) remains a limitation.
Breast cancer
Post-menopausal breast cancer risk is influenced by obesity, partly through increased circulating oestrogen produced by adipose tissue. Weight loss reduces this oestrogen production, which may lower risk.
- Clinical trials: No increased breast cancer incidence has been observed in GLP-1 RA arms of clinical trials compared with placebo
- Observational data: Some studies suggest a neutral or slightly reduced risk in GLP-1 RA users, but the data is limited and follow-up periods are short relative to cancer latency
- Biological plausibility: The weight-loss-mediated reduction in circulating oestrogen could theoretically reduce post-menopausal breast cancer risk, but this is not yet confirmed in the specific context of GLP-1 RA use
Other cancers
Endometrial cancer
Obesity is one of the strongest risk factors for endometrial cancer. Significant weight loss — whether through bariatric surgery or medications — is associated with reduced endometrial cancer risk in observational studies. No clinical trial has specifically evaluated this endpoint for GLP-1 RAs, but the biological rationale is strong.
Kidney cancer
Obesity is also a risk factor for renal cell carcinoma. Early observational data have not shown an increased risk with GLP-1 RA use, and the kidney-protective effects of semaglutide observed in the FLOW trial are reassuring. Dedicated cancer-focused studies are needed.
Liver cancer (hepatocellular carcinoma)
Non-alcoholic fatty liver disease (NAFLD), which is strongly associated with obesity and type 2 diabetes, is a growing risk factor for liver cancer. GLP-1 RAs have shown benefits in reducing liver fat and improving markers of liver inflammation in clinical trials. Some researchers hypothesise that long-term GLP-1 RA use may reduce the progression from fatty liver to cirrhosis and subsequently to liver cancer, but this remains speculative and unproven.
The obesity-cancer connection: could GLP-1 RAs be protective?
Cancer Research UK identifies excess body weight as the second largest preventable cause of cancer in the UK after smoking. Obesity is an established risk factor for at least 13 cancer types, including:
- Colorectal
- Breast (post-menopausal)
- Endometrial (womb)
- Kidney
- Liver
- Oesophageal (adenocarcinoma)
- Pancreatic
- Ovarian
- Gallbladder
If GLP-1 RAs can produce sustained, clinically meaningful weight loss — as demonstrated in the STEP, SELECT and SURMOUNT trials — it is biologically plausible that they could reduce the incidence of obesity-related cancers over time. Bariatric surgery, which produces comparable or greater weight loss, has been shown in large cohort studies to reduce overall cancer incidence by approximately 30 to 40 per cent over 10 to 20 years.
Important caveat: The potential cancer-protective effects of GLP-1 RA-induced weight loss are plausible but unproven. It will take many years of follow-up data to determine whether these medications reduce cancer incidence in the real world. Current prescribing should be based on established benefits (glycaemic control, weight management, cardiovascular risk reduction) rather than speculative cancer prevention.
EMA and MHRA regulatory positions
| Cancer type | Regulatory position (April 2026) | Label warning? |
|---|---|---|
| Medullary thyroid carcinoma | Precautionary contraindication for MTC/MEN2 based on rodent data | Yes |
| Pancreatic cancer | Reviewed and found insufficient evidence for causal link | No specific warning |
| Colorectal cancer | No safety concern identified; some observational data suggest reduced risk | No |
| Breast cancer | No increased risk identified in clinical trials | No |
| Other cancers | No specific safety signals identified | No |
Both agencies emphasise that ongoing pharmacovigilance is essential. The MHRA encourages UK healthcare professionals and patients to report suspected adverse reactions, including cancer diagnoses, through the Yellow Card Scheme. The EMA monitors signals through EudraVigilance.
Advice for UK patients
- Do not stop your GLP-1 medication because of unconfirmed cancer fears. The established benefits for diabetes, weight management and cardiovascular health are well-documented.
- Attend routine screenings: Continue with NHS cancer screening programmes (bowel, breast, cervical) regardless of medication use.
- Report concerns: If you are diagnosed with cancer whilst taking a GLP-1 RA, report it through the Yellow Card Scheme (yellowcard.mhra.gov.uk). This contributes to ongoing safety monitoring.
- Discuss your history: If you have a personal or family history of MTC or MEN2, inform your prescriber — GLP-1 RAs are contraindicated.
- Cancer survivors: Discuss GLP-1 RA use with your oncologist on an individual basis. There is no blanket contraindication beyond MTC/MEN2.
Frequently asked questions
Do GLP-1 medications increase cancer risk?
Current evidence does not confirm an increased cancer risk. The known safety signal relates to thyroid C-cell tumours in rodents, which has not been confirmed in humans. Large clinical trials and observational studies have not identified a consistent increase in risk for any other cancer type.
What does the MHRA say about GLP-1 drugs and cancer?
The MHRA maintains the thyroid precautionary warning and MTC/MEN2 contraindication. No safety alert has been issued linking GLP-1 RAs to increased cancer risk in humans for any other cancer type. Monitoring continues through the Yellow Card Scheme.
Can GLP-1 drugs reduce cancer risk?
Obesity is a risk factor for at least 13 cancer types. By promoting sustained weight loss, GLP-1 RAs may indirectly reduce obesity-related cancer risk over time. Some observational data support this, but it is not yet confirmed by randomised trials.
Is there a link between Ozempic and pancreatic cancer?
Early concerns from the 2010s were not supported by subsequent large clinical trials or regulatory reviews. The EMA and FDA both concluded there was insufficient evidence for a causal link. GLP-1 RAs can rarely cause pancreatitis, which is itself a cancer risk factor, but this indirect pathway does not establish direct causation.
Should cancer survivors avoid GLP-1 medications?
There is no blanket contraindication except for MTC/MEN2. Cancer survivors should discuss their full medical history with their oncologist and prescriber. The decision should be individualised, considering cancer type, time since treatment and potential benefits.
Related guides
Sources
- MHRA — Ozempic, Wegovy, Mounjaro Summary of Product Characteristics (SmPC)
- EMA — Assessment of GLP-1 receptor agonists and pancreatic safety (2014)
- Cancer Research UK — Obesity, weight and cancer (cancerresearchuk.org)
- Marso SP et al. SUSTAIN-6. N Engl J Med 2016; 375:1834-1844
- Marso SP et al. LEADER. N Engl J Med 2016; 375:311-322
- Gerstein HC et al. REWIND. Lancet 2019; 394:121-130
- Wang L et al. GLP-1 receptor agonists and colorectal cancer risk. Diabetes Care 2024
- Bezin J et al. GLP-1 RA and thyroid cancer risk. Diabetes Care 2023; 46(2):384-390
- Sjostrom L et al. Effects of bariatric surgery on cancer incidence. Lancet Oncol 2009; 10:653-662
- NICE — Obesity: identification, assessment and management (CG189)
- BNF — Semaglutide, Liraglutide, Tirzepatide monographs (bnf.nice.org.uk)